Join
Live feed
·
PRReleasevia Quantisnow
Salarius Pharmaceuticals Inc. logo

Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

ByQuantisnow·Wall Street's wire, on your screen.
SLRX· Salarius Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SLRX (Salarius Pharmaceuticals Inc.) and more on Quantisnow.